CE Week 2018: Conference Program Looks at the Digitalization of Everything
The internet of things, robotics, smart homes, wearables, broadband TV, personal electric transportation, connected cars – the world is digitizing and fast. Are you keeping up?
On June 20-21 some of the most influential minds in the emerging tech arena will gather at CE Week, New York City’s largest consumer electronics (CE) and technology event. They’ll be dissecting trends, forecasting hotbeds of activity and looking at the new crop of products that are quickly turning everything digital.
Without spilling all the beans, here’s a preview of what we’ll be discussing during the CE Week Conference Program:
IoT: What's in it for Me?
The Internet is on track to connect virtually everything. That path could create countless consumer benefits but will require overcoming challenges in connectivity and security. A panel of experts will examine where IoT is poised to have its greatest impact, and how it can enable a safer, smarter world.
Robots: From Roomba to Rosie
While the consumer market for robots is largely limited to toys and home cleaning machines, ever-more sophisticated robots are moving into tasks such as warehouse operations and food service. We discuss the growing role that robots are taking on behind the scenes and how home robotics are set to evolve.
Smart Homes: Opening Doors to Connected Product Suites
It's become almost trivial for companies to add smart voice integration to their products. But the growing sophistication of smart homes is fueling a market for integrated suites of sensors and new attention to home infrastructure. We look at the core of the smart home today and assess its value.
A Glance at the Future: Smartwatches and Wearables Target the Mainstream
Despite pockets of success, most companies in the smartwatch market continue to struggle with a product that relies mostly on notifications and health tracking. Still, the past year has seen major watch companies jump in and the category continues to see improvements in areas such as battery life, display brightness and versatility. In our panel, we'll look at the state of wearables and whether they can move beyond the early adopters.
Ready, Willing but Not Cable: How Broadband is Defining Home Entertainment
Every month, more consumers turn away from traditional pay TV subscriptions to an assortment of on-demand and increasingly linear options filled with billions of dollars' worth of original content investment. Broadband TV can be enjoyed nearly anywhere but consumers must navigate a fractured landscape that can pile on subscriptions. A panel of industry leaders will discuss the progress of broadband TV and how the customer experience can be improved.
Getting There from Here: Personal Electric Transportation and the Urban Commute
As cars go electric, the door has opened for a host of other products that can help get people around town. They range from battery-powered skateboards, scooters and e-bikes to one-person vehicles that all offer tradeoffs in size, weight, safety and ease of use. Meanwhile, many municipal laws still don't allow for many of these personal transporters. We’ll discuss the explosion in new forms of short-commute personal vehicles and how they might create new commuting options.
Driving to the Future: Cars Are Doing It for Themselves
Increasingly, cars are leaving the pump in favor of electric charging stations, one of countless destinations to which they are increasingly able to drive to themselves. We explore the timetable to autonomous vehicles, what will it mean for how consumers commute, and what opportunities such vehicles provide for the industry.
Other session topics include 5G, smartphones, digital health, and retail.
CE Week will take place at the Jacob Javits Convention Center, June 20-21, 2018. To register for CE Week 2018 and see the full schedule of events, visit www.ceweekny.com. Follow CE Week on Facebook and Twitter, and use the official CE Week hashtag, #CEWeekNY.
About CE Week
Entering its 11th year, CE Week 2018 will celebrate all things tech on June 20-21 at the Jacob K. Javits Convention Center in NYC. The event serves as the epicenter for innovation, emerging tech trends and insights, and building connections in the North American technology and CE retail space. CE Week is produced annually by CT Lab Global Media, a partnership between IFA, the world’s largest consumer electronics trade show, and NAPCO Media, a U.S. business-to-business media company that offers consumer electronics and home appliances brands an unrivaled platform to connect with retailers, manufacturers, distributors and buying groups. For more information, visit www.ceweekny.com and keep up with our latest news on Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180417006317/en/
Contact information
Messe Berlin
IFA PR Manager
Nicole von der Ropp
Tel.: +49
(0)30 / 3038-2217
vonderropp@messe-berlin.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom